Lung Cancer Research Foundation (LCRF) Company Profile

Background

The Lung Cancer Research Foundation (LCRF) is a nonprofit organization dedicated to improving lung cancer outcomes by funding research focused on prevention, diagnosis, treatment, and cure. Established in 2005 and incorporated in New York, LCRF envisions a world free of lung cancer.

Key Strategic Focus

LCRF's strategic focus centers on:

Funding Innovative Research: Supporting early-career investigators to advance understanding and treatment of lung cancer.

Community Engagement: Fostering connections with patients, caregivers, healthcare professionals, and researchers to build a dedicated network advocating for lung cancer research.

Educational Programs: Providing resources such as the Lung Cancer Support Line, clinical trial search tools, and free educational materials for patients and caregivers.

Awareness Initiatives: Hosting community events nationwide through the Free to Breathe events program to promote lung cancer awareness.

Financials and Funding

LCRF's financial highlights for the year ending December 31, 2022, include:

Total Income: $6,493,024

Contributions and grants: $4,924,583

Special events (net): $1,522,677

Investment income: $28,829

In-kind contributions: $16,935

Total Expenses: $6,416,802

Program services: $5,570,258 (87%)

Fundraising expenses: $567,237 (9%)

Administrative expenses: $279,307 (4%)

Net Assets: $3,584,220

Pipeline Development

LCRF has funded 428 research grants totaling nearly $48 million, supporting projects that aim to extend survival and improve the quality of life for lung cancer patients.

Technological Platform and Innovation

LCRF emphasizes:

Proprietary Technologies: Funding research that explores novel diagnostic tools and treatment methodologies.

Scientific Methodologies: Supporting studies utilizing advanced assays and machine learning algorithms to enhance lung cancer detection and treatment.

Leadership Team

Aubrey Rhodes: Executive Director since July 1, 2023.

Reina Honts: Chair of the Board, Management Consultant.

Antoinette Wozniak: Chief Scientific Officer.

Sheila Sullivan: Senior Director, Marketing & Communications.

Leadership Changes

Aubrey Rhodes assumed the role of Executive Director on July 1, 2023, succeeding Dennis Chillemi, who received $248,630 in compensation in 2021.

Competitor Profile

Market Insights and Dynamics

Lung cancer remains the leading cause of cancer mortality, yet it receives significantly less research funding per death compared to other cancers.

Competitor Analysis

Lung Cancer Foundation of America (LCFA): Focuses on improving survivorship through funding transformative science and raising public awareness.

Strategic Collaborations and Partnerships

LCRF collaborates with various partners to enhance its research capabilities and outreach efforts.

Operational Insights

LCRF's commitment to funding early-career investigators and its extensive grant portfolio position it as a leader in lung cancer research funding.

Strategic Opportunities and Future Directions

By 2030, LCRF aims to nearly double its annual research investment to $5 million, dedicating at least 50% of its net revenue to transformative projects that advance lung cancer survival.